Clinical and Immunopathological Aspects of Cutaneous, Mucocutaneous, Visceral, and Post-kala-azar Leishmaniasis

The disease Leishmaniasis is a neglected illness with two major forms clinically including cutaneous leishmaniasis and visceral leishmaniasis. From almost 100 endemic countries, an estimated one million additional records of leishmaniasis each year are documented. In the past decade, the number of confirmed cases of visceral leishmaniasis has decreased dramatically as a consequence of an improved approach to diagnosis and care and more intensive, though usual cycles may play a role in the severity of disease transmission. In the cutaneous form of leishmania disease (CL), the lesion is located in some parts like the face and arms. Whereas a visceral form of leishmania (VL) disease the parasite infects internal organs such as the liver and pancreas. Reports from the World Health Organization (WHO) record leishmaniasis as one of the ignored temperate disorders for which the improvement of novel therapies is required. Significant evidence gaps remain, and new methods are required before leishmaniasis can be definitively managed. Recent advances in our understanding of leishmaniasis and its clinical manifestations, as well as the immunological aspects of leishmaniasis, are the key objectives of this study.